Boundless Bio

A company operating in the field of oncology and currently in the clinical trial phase is seeking to establish a new paradigm in cancer treatment. It focuses on patients with an increased number of oncogenes, targeting extrachromosomal DNA (ecDNA), which is one of the causes of oncogene amplification, found in more than 14% of cancer patients.

The company is registered in Delaware.